PAX5 and nasopharyngeal carcinoma: CCR7, CD22, TNFRSF13C, CR2, CD69, PAX5, and MS4A1 expression levels were significantly lower in advanced stages, with the highest expression level found in patients with stage I NPC (Fig. S8A).